FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293770167> ?p ?o ?g. }

• W4293770167 abstract "Background: Acute and chronic neurodegenerative diseases represent an immense socioeconomic burden that drives the need for new disease modifying drugs. Common pathogenic mechanisms in these diseases are evident, suggesting that a platform neuroprotective therapy may offer effective treatments. Here we present evidence for the mode of pharmacological action of a novel neuroprotective low molecular weight dextran sulphate drug called ILB®. The working hypothesis was that ILB® acts via the activation of heparin-binding growth factors (HBGF). Methods: Pre-clinical and clinical (healthy people and patients with ALS) in vitro and in vivo studies evaluated the mode of action of ILB®. In vitro binding studies, functional assays and gene expression analyses were followed by the assessment of the drug effects in an animal model of severe traumatic brain injury (sTBI) using gene expression studies followed by functional analysis. Clinical data, to assess the hypothesized mode of action, are also presented from early phase clinical trials. Results: ILB® lengthened APTT time, acted as a competitive inhibitor for HGF-Glypican-3 binding, effected pulse release of heparin-binding growth factors (HBGF) into the circulation and modulated growth factor signaling pathways. Gene expression analysis demonstrated substantial similarities in the functional dysregulation induced by sTBI and various human neurodegenerative conditions and supported a cascading effect of ILB® on growth factor activation, followed by gene expression changes with profound beneficial effect on molecular and cellular functions affected by these diseases. The transcriptional signature of ILB® relevant to cell survival, inflammation, glutamate signaling, metabolism and synaptogenesis, are consistent with the activation of neuroprotective growth factors as was the ability of ILB® to elevate circulating levels of HGF in animal models and humans. Conclusion: ILB® releases, redistributes and modulates the bioactivity of HBGF that target disease compromised nervous tissues to initiate a cascade of transcriptional, metabolic and immunological effects that control glutamate toxicity, normalize tissue bioenergetics, and resolve inflammation to improve tissue function. This unique mechanism of action mobilizes and modulates naturally occurring tissue repair mechanisms to restore cellular homeostasis and function. The identified pharmacological impact of ILB® supports the potential to treat various acute and chronic neurodegenerative disease, including sTBI and ALS." @default.
• W4293770167 created "2022-08-31" @default.
• W4293770167 creator A5007788517 @default.
• W4293770167 creator A5017691776 @default.
• W4293770167 creator A5024646408 @default.
• W4293770167 creator A5028403951 @default.
• W4293770167 creator A5047972775 @default.
• W4293770167 creator A5066434829 @default.
• W4293770167 creator A5069468882 @default.
• W4293770167 creator A5070438968 @default.
• W4293770167 creator A5077540699 @default.
• W4293770167 creator A5079719651 @default.
• W4293770167 creator A5082703510 @default.
• W4293770167 creator A5090483904 @default.
• W4293770167 date "2022-08-30" @default.
• W4293770167 modified "2023-09-30" @default.
• W4293770167 title "The mechanism of action of a novel neuroprotective low molecular weight dextran sulphate: New platform therapy for neurodegenerative diseases like Amyotrophic Lateral Sclerosis" @default.
• W4293770167 cites W1098620786 @default.
• W4293770167 cites W1540792924 @default.
• W4293770167 cites W1963490521 @default.
• W4293770167 cites W1979589320 @default.
• W4293770167 cites W2014716738 @default.
• W4293770167 cites W2040678584 @default.
• W4293770167 cites W2063126267 @default.
• W4293770167 cites W2068394692 @default.
• W4293770167 cites W2101321540 @default.
• W4293770167 cites W2103044571 @default.
• W4293770167 cites W2129780146 @default.
• W4293770167 cites W2154549928 @default.
• W4293770167 cites W2166522212 @default.
• W4293770167 cites W2171380576 @default.
• W4293770167 cites W2500642579 @default.
• W4293770167 cites W2520222164 @default.
• W4293770167 cites W2553902009 @default.
• W4293770167 cites W2559830163 @default.
• W4293770167 cites W2570047468 @default.
• W4293770167 cites W2586753777 @default.
• W4293770167 cites W2756086301 @default.
• W4293770167 cites W2885679472 @default.
• W4293770167 cites W2891582473 @default.
• W4293770167 cites W2901734506 @default.
• W4293770167 cites W2903781946 @default.
• W4293770167 cites W2905127652 @default.
• W4293770167 cites W2912466497 @default.
• W4293770167 cites W2922667573 @default.
• W4293770167 cites W2965305206 @default.
• W4293770167 cites W2965434187 @default.
• W4293770167 cites W2966772209 @default.
• W4293770167 cites W2973215277 @default.
• W4293770167 cites W2977784403 @default.
• W4293770167 cites W2990587637 @default.
• W4293770167 cites W3015185879 @default.
• W4293770167 cites W3029421884 @default.
• W4293770167 cites W3030874002 @default.
• W4293770167 cites W3084284728 @default.
• W4293770167 cites W3085092056 @default.
• W4293770167 cites W3087508426 @default.
• W4293770167 cites W3091396307 @default.
• W4293770167 cites W3094053673 @default.
• W4293770167 cites W3099257908 @default.
• W4293770167 cites W3113412054 @default.
• W4293770167 cites W3119933590 @default.
• W4293770167 cites W3129758780 @default.
• W4293770167 cites W3143417206 @default.
• W4293770167 cites W3154668342 @default.
• W4293770167 cites W3168550974 @default.
• W4293770167 cites W3171004075 @default.
• W4293770167 cites W3174381563 @default.
• W4293770167 cites W3176175333 @default.
• W4293770167 cites W3188727573 @default.
• W4293770167 cites W3216005154 @default.
• W4293770167 cites W4200618221 @default.
• W4293770167 cites W4214577587 @default.
• W4293770167 cites W4214665053 @default.
• W4293770167 cites W4220710167 @default.
• W4293770167 cites W4229633773 @default.
• W4293770167 cites W4281482998 @default.
• W4293770167 cites W4289175152 @default.
• W4293770167 doi "https://doi.org/10.3389/fphar.2022.983853" @default.
• W4293770167 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36110516" @default.
• W4293770167 hasPublicationYear "2022" @default.
• W4293770167 type Work @default.
• W4293770167 citedByCount "4" @default.
• W4293770167 countsByYear W42937701672022 @default.
• W4293770167 countsByYear W42937701672023 @default.
• W4293770167 crossrefType "journal-article" @default.
• W4293770167 hasAuthorship W4293770167A5007788517 @default.
• W4293770167 hasAuthorship W4293770167A5017691776 @default.
• W4293770167 hasAuthorship W4293770167A5024646408 @default.
• W4293770167 hasAuthorship W4293770167A5028403951 @default.
• W4293770167 hasAuthorship W4293770167A5047972775 @default.
• W4293770167 hasAuthorship W4293770167A5066434829 @default.
• W4293770167 hasAuthorship W4293770167A5069468882 @default.
• W4293770167 hasAuthorship W4293770167A5070438968 @default.
• W4293770167 hasAuthorship W4293770167A5077540699 @default.
• W4293770167 hasAuthorship W4293770167A5079719651 @default.
• W4293770167 hasAuthorship W4293770167A5082703510 @default.
• W4293770167 hasAuthorship W4293770167A5090483904 @default.
• W4293770167 hasBestOaLocation W42937701671 @default.
• W4293770167 hasConcept C121587506 @default.

• next